Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
DMAC 
DiaMedica Therapeutics Inc (DMAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: DMAC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.67
1 Year Target Price $9.67
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 31.02% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 167.25M USD | Price to earnings Ratio - | 1Y Target Price 9.67 |
Price to earnings Ratio - | 1Y Target Price 9.67 | ||
Volume (30-day avg) 4 | Beta 1.2 | 52 Weeks Range 2.80 - 6.82 | Updated Date 07/1/2025 |
52 Weeks Range 2.80 - 6.82 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.27% | Return on Equity (TTM) -67.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 131241513 | Price to Sales(TTM) - |
Enterprise Value 131241513 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.96 | Shares Outstanding 42883500 | Shares Floating 24338082 |
Shares Outstanding 42883500 | Shares Floating 24338082 | ||
Percent Insiders 26.28 | Percent Institutions 35.99 |
Analyst Ratings
Rating 2 | Target Price 9.67 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
DiaMedica Therapeutics Inc
Company Overview
History and Background
DiaMedica Therapeutics Inc. was founded in 2004. It is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. The company's lead product candidate is DM199.
Core Business Areas
- Neurological Diseases: Developing DM199 for acute ischemic stroke (AIS) and other neurological conditions.
- Kidney Diseases: Investigating DM199 for the treatment of chronic kidney disease (CKD).
- DM199 Development: Researching and developing DM199, a recombinant human tissue kallikrein-1 (KLK1) protein.
Leadership and Structure
Rick Pauls is the Chief Executive Officer. The company has a board of directors overseeing strategic direction. The organizational structure includes research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- DM199: DM199 is DiaMedica's lead product candidate currently in clinical trials for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Market share data is currently not available as the product is in development and not yet commercially available. Competitors include companies developing similar therapies for stroke and kidney diseases such as Boehringer Ingelheim, Genentech (Roche), and other biotechnology companies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. Development of novel therapies for neurological and kidney diseases is a key area of focus. The industry is characterized by high risk, long development timelines, and significant regulatory hurdles.
Positioning
DiaMedica is positioning DM199 as a potentially differentiated therapy for stroke and kidney diseases, targeting a novel mechanism of action (KLK1 pathway). Their competitive advantage, if proven, would be superior efficacy or safety profiles. It is not yet well positioned in the market, because the treatment hasn't yet gone through the clinical trial phase.
Total Addressable Market (TAM)
The TAM for stroke and CKD therapies is substantial, estimated in the billions of dollars. DiaMedica is aiming to capture a portion of this market with DM199. Market Value is expected to be approximately $50 billion in the coming years.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting the KLK1 pathway
- Potential to address unmet needs in stroke and kidney disease
- Intellectual property protection for DM199
- Experienced management team
Weaknesses
- Dependence on successful clinical trial outcomes for DM199
- Limited financial resources compared to larger pharmaceutical companies
- Uncertainty regarding regulatory approval
- No product currently generating revenue
Opportunities
- Positive clinical trial results could lead to significant market value increase
- Potential partnerships with larger pharmaceutical companies
- Expansion into new indications for DM199
- Growing prevalence of stroke and kidney disease
Threats
- Failure of clinical trials
- Competition from established therapies and other emerging treatments
- Regulatory setbacks
- Difficulty raising capital
Competitors and Market Share
Key Competitors
- LLY
- NVO
- SNY
- GILD
Competitive Landscape
DiaMedica faces significant competition from larger pharmaceutical companies with established therapies and greater financial resources. Its success depends on demonstrating superior efficacy and safety of DM199.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by development of DM199, progressing through clinical trials.
Future Projections: Future growth depends on successful completion of clinical trials and regulatory approval of DM199. Analyst estimates vary widely depending on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials for DM199 in AIS and CKD, and exploring potential partnerships.
Summary
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company with potential, but faces high risk. The success of the company hinges on the successful clinical development and regulatory approval of DM199, its lead product candidate. It needs to secure additional funding to continue its clinical trials. The company should look out for failures of clinical trials, competition from established therapies and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports (where available)
Disclaimers:
This analysis is based on available information and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DiaMedica Therapeutics Inc
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2008-01-04 | President, CEO & Director Mr. Dietrich John Pauls MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 27 | Website https://www.diamedica.com |
Full time employees 27 | Website https://www.diamedica.com | ||
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.